Blockade of the phagocytosis inhibitor CD47 with the antibody magrolimab has demonstrated futility with an increased risk of death in patients with acute myeloid leukemia (AML) (phase III trial ENHANCE III - NCT05079230). Here, CD47 is linked to acute myeloid leukemia.